Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

The proliferation of ultra-expensive drugs has sparked debate on their sustainability and affordability. Medicare Part D's share of annual spending on these drugs increased by 1,170 percent between 2012 and 2018, largely because the number of beneficiaries receiving them increased during this period.

Automated summary

The proliferation of ultra-expensive drugs led to a significant increase in annual spending on these drugs by Medicare Part D, largely due to the rise in the number of beneficiaries receiving them from 2012 to 2018.